Results 111 to 120 of about 24,253,245 (291)

High Prevalence and Risk Factors for Infection with Human T-Lymphotropic Viruses 1 and 2 in the Municipality of Ananindeua, Pará, Northern Brazil

open access: yesViruses
This descriptive, observational, cross-sectional study evaluated HTLV-1 and HTLV-2 infections in Ananindeua, northern Brazil. Individuals were screened for anti-HTLV-1/2 using ELISA (Murex HTLV-I + II, DiaSorin).
Dara da Costa Soares   +10 more
doaj   +1 more source

Crosstalk Between Intratumoral Microbes and Tumor Immunity: Implications for Tumor Therapy

open access: yesCancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Emerging studies indicate that microbes are present in tumor cells and immune cells. Intratumoral microbiota (ITM) constitute an important component of the tumor immune microenvironment (TIME) and have an important impact on tumor progression and treatment. Objective Through the general elaboration of ITM represented by bacteria and
Fengxue Li   +13 more
wiley   +1 more source

Tocilizumab has no direct effect on cell lines infected with human T-cell leukemia virus type 1

open access: yesJournal of International Medical Research, 2021
Objective It remains unclear whether human T-cell leukemia virus type 1 (HTLV-1) infection influences therapeutic responses in patients with rheumatic diseases and whether immunosuppressive treatments increase the risk of HTLV-1-related complications in ...
Yushiro Endo   +9 more
doaj   +1 more source

Alpha interferon restricts human T-lymphotropic virus type 1 and 2 De Novo infection through PKR activation [PDF]

open access: yes, 2013
International audienceType I interferon (IFN-I) inhibits the replication of different viruses. However, the effect of IFN-I on the human T-lymphotropic virus type 1 (HTLV-1) viral cycle is controversial.
Alais, Sandrine   +7 more
core   +4 more sources

Harnessing viral footprints in circulating free DNA (cfDNA) for early cancer detection: A focus on liquid‐biopsy‐based screening

open access: yesInternational Journal of Cancer, Volume 158, Issue 3, Page 511-526, 1 February 2026.
Abstract Viral infections play a significant role in cancer development, making detecting viral signatures a promising approach for early cancer diagnosis. Circulating free DNA (cfDNA), released into the bloodstream by tumors and other cells, has emerged as a powerful biomarker for non‐invasive cancer screening.
Richard Donkor Amponsah   +4 more
wiley   +1 more source

HTLV-1 bZIP factor impairs DNA mismatch repair system [PDF]

open access: green, 2023
Maki Sakurada-Aono   +16 more
openalex   +1 more source

Does counseling increase sustained benefit of HAART among prison inmates after release to the community? [PDF]

open access: yes, 2005
The lack of sustained effectiveness of HAART after release to the community of HIV-infected inmates treated in prison was well demonstrated by Springer et al. in a recent article.
Babudieri, Sergio   +4 more
core   +1 more source

Tumor Immunotherapy and Microbiome: From Bench‐to‐Bedside Applications

open access: yesMedComm, Volume 7, Issue 2, February 2026.
The microbiome is related to the efficacy of immunotherapy and can be utilized to predict the efficacy and adverse reactions of immunotherapy. Microbiome‐targeted intervention strategies can improve the efficacy of ICI, but necessitating more comprehensive exploration.
Anqi Lin   +12 more
wiley   +1 more source

Susceptibility of Primary HTLV-1 Isolates from Patients with HTLV-1-Associated Myelopathy to Reverse Transcriptase Inhibitors

open access: yesViruses, 2011
Since human T-lymphotropic virus type 1 (HTLV-1)-associated diseases are associated with a high HTLV-1 load, reducing this load may treat or prevent disease.
Antonio Mastino   +6 more
doaj   +1 more source

Status of soluble ST2 levels in serum of HTLV-1 infected individuals [PDF]

open access: yes, 2015
ST2 is a member of IL-1 receptor family expressed on Th2 cells and regulates Th2 responces. The gene of ST2 encodes soluble ST2 (sST2) and the transmembrane ST2 (ST2L) isoforms through alternative mRNA splicing.
Avval, Farnaz Zahedi   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy